Ask about Semaglutide
Get a grounded answer across clinical evidence, community patterns, and risks.
Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
GLP-1 receptor agonist
Mechanism of Action
Activates GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite.
Note: Diabetes (Ozempic) and weight management (Wegovy)
Semaglutide: GLP-1 Receptor Agonist
Semaglutide is backed by 1,345 published articles and 621 clinical trials. Self-reported weight loss observations align closely with clinical findings, where reductions often exceed 15–20% of body weight in long-term settings. FDA-approved for both diabetes and weight management, it carries a clinical effect score of 98 for weight loss and 95 for blood sugar control.
Reported Outcomes
Clinical grade reflects published research; Community grade reflects user reports (n=2,207).
Reduction in body weight
Semaglutide consistently demonstrates substantial weight loss in both diabetic and non-diabetic populations, with reductions often exceeding 15-20% in long-term real-world and clinical settings. It outperforms other GLP-1 receptor agonists like liraglutide in head-to-head comparisons.
Effects on sleep quality
Improvements in sleep quality and resolution of obstructive sleep apnea (OSA) are observed, largely attributed to substantial weight loss.
Reduced hunger and food cravings
Treatment is strongly associated with reduced appetite and increased satiety, which correlates with changes in taste perception (increased sweet/salty sensitivity).
Improved glycemic control and insulin sensitivity
Semaglutide provides robust glycemic control, with significant reductions in HbA1c levels observed in clinical trials and real-world settings for Type 2 Diabetes.
Effects on mood and cognitive function
Large real-world cohorts indicate a reduced risk of depression and suicidal ideation with semaglutide compared to other obesity medications, despite isolated case reports of mood changes or suicidality.
Changes in muscle vs fat ratio
Treatment significantly reduces fat mass and visceral fat; while lean muscle mass also decreases, the ratio of muscle-to-weight often improves, though targeted exercise is recommended to mitigate muscle loss.
Changes in energy and fatigue levels
Effects on heart health markers
Real-world data indicates a significantly lower risk of major adverse cardiovascular events (MACE) and improvements in blood pressure and lipid profiles. Benefits extend to heart failure outcomes and pulmonary artery pressure reductions.
Who Discusses Semaglutide
From community reports with demographic data.
Gender
n=169
Age Distribution (limited data)
n=56
Side Effects
Based on 272 user reports (n=272). Frequency indicates how often each was mentioned.
Common (>5%)
Uncommon (1-5%)
Risks & Warnings
Important safety considerations based on clinical data and community reports.
Pancreatitis
Rare but serious. Stop medication and seek care for severe persistent abdominal pain.
Gallbladder Issues
Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.
Thyroid Concerns
GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.
Muscle Loss
Rapid weight loss may include muscle. Adequate protein intake and resistance training recommended.
Hypoglycemia Risk
Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.
Psychiatric Effects
Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.
Hair Loss
May occur with rapid weight loss. Usually temporary (telogen effluvium). Ensure adequate nutrition.
Gastrointestinal Issues
GI side effects are the most commonly reported. Usually improve over time with slow titration.
Injection Site Reactions
Local reactions are common and usually mild. Rotate injection sites.
Dosing
Standard Protocol
- Starting Dose
- 0.25mg weekly
- Titration
- Increase every 4 weeks: 0.25→0.5→1→1.7→2.4mg
- Half-life
- ~7 days
- Administration
- Subcutaneous injection (Ozempic/Wegovy) or oral (Rybelsus), once weekly
- FDA-Approved Doses
- 0.25mg 0.5mg 1mg 1.7mg 2.4mg
Community Dosing Patterns
Based on 384 mentions
Community-reported patterns, not medical advice.
Pricing
Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.
We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.
US Research Grade
Single small vial from US domestic vendors
US Research (Bulk)
Per-dose equivalent when buying larger US vials
China Research
Per-vial when buying 10-pack from Chinese vendors
Research
Key Studies
Clin Pharmacokinet (2023)
Int J Mol Sci (2023)
medRxiv (2023)
Nutrients (2023)
EClinicalMedicine (2023)
Commonly Stacked With
From community members' documented stacks involving Semaglutide.
Switching Patterns
Based on 341 discussions about switching to or from Semaglutide.
→ Switching FROM
Users who switched to Semaglutide
← Switching TO
Users who switched from Semaglutide